Enjoy complimentary customisation on priority with our Enterprise License!
Hemophilia B, commonly known as Christmas disease, is a genetic blood coagulation disorder that is caused due to factor IX deficiency. Even though this is an inherited disease, approximately one-third of the cases occur due to spontaneous gene mutation. Analysts estimate the market for hemophilia B to surpass US$ 2 billion due to the advent of plasma-derived and recombinant factor replacement therapeutics.
Technavio’s market research analysts estimate the Americas to account for approximately 44% of the total market revenue during the forecast period. This region’s domination of the market can be attributed to the increase in prophylactic treatment and development of long-acting hemophilia B therapeutic products.
The launch of long-acting drugs for factor replacement therapies and its acceptance among the end users is expected to drive market growth by augmenting the revenues generated by companies. Competitiveness in this market is expected to deepen with an increase in strategic alliances and technological advancements.
Leading vendors in this market are –
Other prominent vendors in this market are Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen, Catalyst Biosciences, CSL Behring, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Kedrion, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, Swedish Orphan Biovitrum, and uniQure.
The moderate hemophilia B segment accounts for approximately 37% of the total market size and is expected to dominate over the other two segments during the forecast period. In moderate hemophilia B, the activity of factor IX is in the range of 1 to 5% and maybe associated with bleeding episodes after injuries.
In this market research report, analysts estimate the on-demand therapy segment to account for more than 80% of the total market share. The on-demand therapy is widely popular in developing economies like APAC and EMEA, where access to proper healthcare facilities is limited. Also, low awareness pertaining to disease prophylaxis is another factor that is expected to promote the implementation of on-demand treatments in these regions.
Technavio also offers customization on reports based on specific client requirement.
Global Hemophilia Market 2014-2018
Global Healthcare IT Spending - Market Analysis 2015-2019
Global Preimplantation Genetic Diagnosis (PGD) Market 2014-2018
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.